Allergy Therapeutics plc
AGY.L · LSE
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | £378,932 | £175,937 | £7,033 | £13,342,606 |
| - Cash | £12,790 | £12,915 | £14,845 | £20,515 |
| + Debt | £60,089 | £30,988 | £35,989 | £10,529 |
| Enterprise Value | £426,231 | £194,010 | £28,177 | £13,332,620 |
| Revenue | £55,044 | £55,199 | £59,587 | £72,768 |
| % Growth | -0.3% | -7.4% | -18.1% | – |
| Gross Profit | £25,130 | £29,737 | £32,691 | £48,954 |
| % Margin | 45.7% | 53.9% | 54.9% | 67.3% |
| EBITDA | -£29,429 | -£30,740 | -£36,240 | -£8,690 |
| % Margin | -53.5% | -55.7% | -60.8% | -11.9% |
| Net Income | -£40,132 | -£40,216 | -£43,071 | -£13,776 |
| % Margin | -72.9% | -72.9% | -72.3% | -18.9% |
| EPS Diluted | -0.008 | -0.011 | -0.064 | -0.021 |
| % Growth | 21.5% | 83.4% | -200.5% | – |
| Operating Cash Flow | -£28,717 | -£32,138 | -£30,916 | -£14,111 |
| Capital Expenditures | -£3,264 | -£3,401 | -£4,669 | -£3,056 |
| Free Cash Flow | -£31,981 | -£35,539 | -£35,585 | -£17,167 |